Tarsus Pharmaceuticals Valuation Multiples

Tarsus Pharmaceuticals Overview

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Founded

2016

HQ

Employees

370

Website

tarsusrx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $518M

Net Income: ($57M)

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

Tarsus Pharmaceuticals Financials

Tarsus Pharmaceuticals reported last 12-month revenue of $518M.

In the same LTM period, Tarsus Pharmaceuticals generated $483M in gross profit and had net loss of ($57M).

Tarsus Pharmaceuticals P&L

In the most recent fiscal year, Tarsus Pharmaceuticals reported revenue of $451M and EBITDA of ($54M).

Tarsus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals has current market cap of $3B, and enterprise value of $3B.

Tarsus Pharmaceuticals' stock price is $72.43.

Tarsus Pharmaceuticals Valuation Multiples

Tarsus Pharmaceuticals trades at 5.3x EV/Revenue multiple, and (50.5x) EV/EBITDA.

Tarsus Pharmaceuticals Financial Valuation Multiples

As of April 10, 2026, Tarsus Pharmaceuticals has market cap of $3B and EV of $3B.

Equity research analysts estimate Tarsus Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Tarsus Pharmaceuticals has a P/E ratio of (53.7x).

Tarsus Pharmaceuticals Margins & Growth Rates

Tarsus Pharmaceuticals' revenue in the last 12 month grew by 45%.

Tarsus Pharmaceuticals' revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $1.3M for the same period.

Tarsus Pharmaceuticals' rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tarsus Pharmaceuticals' rule of X is 128% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Tarsus Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Tarsus Pharmaceuticals M&A Activity

Tarsus Pharmaceuticals acquired XXX companies to date.

Last acquisition by Tarsus Pharmaceuticals was on XXXXXXXX, XXXXX. Tarsus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Tarsus Pharmaceuticals Investment Activity

Tarsus Pharmaceuticals invested in XXX companies to date.

Tarsus Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Tarsus Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).